NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $0.51, but opened at $0.62. NovaBay Pharmaceuticals shares last traded at $0.62, with a volume of 14,184 shares traded.
A number of research firms have recently commented on NBY. Zacks Investment Research raised NovaBay Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target on the stock in a research report on Wednesday, November 20th. LADENBURG THALM/SH SH initiated coverage on NovaBay Pharmaceuticals in a research report on Wednesday, September 18th. They issued a “buy” rating and a $1.10 price objective for the company.
The stock’s 50 day simple moving average is $0.68 and its two-hundred day simple moving average is $1.02.
An institutional investor recently bought a new position in NovaBay Pharmaceuticals stock. Jane Street Group LLC bought a new position in NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 37,287 shares of the biopharmaceutical company’s stock, valued at approximately $63,000. Jane Street Group LLC owned 0.18% of NovaBay Pharmaceuticals at the end of the most recent quarter.
About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Recommended Story: What is the Rule of 72?
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.